FDA Approves Revolutionary CRISPR Gene Editing Treatment for Sickle Cell Disease
TL;DR Summary
The FDA has approved two treatments for sickle cell disease, including the first-ever gene editing therapy using CRISPR. These approvals offer hope for the 100,000 Americans, mostly Black individuals, suffering from the debilitating blood disorder. However, obstacles such as limited access to authorized medical centers, individualized gene editing procedures, patient tolerance, high costs, and potential insurance obstacles may limit the reach of these treatments.
- F.D.A. Approves 2 Sickle Cell Treatments, One Using CRISPR Gene Editing The New York Times
- Casgevy: First CRISPR gene-editing treatment approved in U.S. CNBC
- FDA approves two gene therapies for sickle cell, bringing hope to thousands with the disease CNN
- The Download: inside the first CRISPR treatment, and smarter robots MIT Technology Review
- Listen: Sickle Cell Cure, Job Gains, More Bloomberg
Reading Insights
Total Reads
0
Unique Readers
12
Time Saved
1 min
vs 2 min read
Condensed
81%
339 → 64 words
Want the full story? Read the original article
Read on The New York Times